1
Return

Daraxonrasib in pancreatic cancer: When progress disrupts practice

delete2026-08-07
delete0
PRE
AI
A
Asfar S. Azmi *
P
Philip A. Philip *
DOI：10.1016/j.drudis.2026.104761delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
• Daraxonrasib may redefine standards in pancreatic cancer care. • Clinical progress can disrupt established drug development pathways. • Pan-RAS inhibition challenges assumptions about stromal barriers. • Expanded access may complicate future clinical trial enrollment. • Future trials may require adaptive and backbone-based designs.

Journal

Drug Discovery Today cover
Drug Discovery Today
IF:
7.5
Papers:
6.3K
Citations:
2.3W

Organization

H
Henry Ford Health System
Scholars:
9.1K
Papers: 7.4K
Citations: 3.4K
W
wayne state university
Scholars:
2.0W
Papers: 1.6W
Citations: 17
Cited Papers

Cited Papers

Citing Papers

Citing Papers